Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids, aiming to improve patient experience through rapid delivery and reduced treatment burden [3] - Halozyme has impacted one million patient lives through post-marketing use of ten commercialized products across more than 100 global markets [3] Product and Technology - Halozyme has licensed its ENHANZE® technology to major pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and AbbVie, among others [3] - The company also develops and commercializes drug-device combination products using advanced auto-injector technologies, which offer advantages such as improved convenience, reliability, and patient comfort [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing product development programs with partners like Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 4:20 PM PT / 7:20 PM ET [1] - A live audio webcast of the presentation will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [2]

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared t ...

Core Insights - EyePoint Pharmaceuticals, Inc. is set to host a conference call on May 7, 2025, to discuss its Q1 2025 financial results and recent corporate developments [1] - The company focuses on developing innovative therapeutics for serious retinal diseases, utilizing its proprietary Durasert E™ technology for sustained intraocular drug delivery [3][4] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with a commercial-ready manufacturing facility in Northbridge, Massachusetts [4] - The lead product candidate, DURAVYU™, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has completed a Phase 2 trial for diabetic macular edema (DME) [3][5] Pipeline and Technology - The company's pipeline includes EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E™ to potentially enhance outcomes in serious retinal diseases [4] - Durasert technology has been safely administered to thousands of patient eyes across four FDA-approved products for various disease indications [4] Licensing and Regulatory Status - Vorolanib, the active ingredient in DURAVYU™, is exclusively licensed to EyePoint by Equinox Sciences for the treatment of ophthalmic diseases outside of specific Asian markets [5] - DURAVYU™ has received conditional acceptance from the FDA as the proprietary name for EYP-1901, but it remains investigational and has not yet been approved by the FDA [5]

Core Viewpoint - Ocular Therapeutix, Inc. is actively participating in several investor and scientific conferences in May 2025 to showcase its advancements in retinal therapies and engage with the investment community [1][2][3]. Upcoming Investor Conferences - Ocular Therapeutix will present at the Citizens JMP Life Sciences Conference on May 7, 2025, at 9:00 AM ET in New York, NY, with CEO Pravin U. Dugel as the presenter [2]. - The company will also participate in the Bank of America 2025 Global Healthcare Conference on May 13, 2025, at 9:20 AM PT in Las Vegas, NV, again featuring CEO Pravin U. Dugel [2]. Upcoming Scientific Conferences - At the Eyecelerator @ Park City 2025, Ocular will have a panel titled "Retina in Office" on May 2, 2025, focusing on novel drug delivery approaches for glaucoma and retina, with Chief Medical Officer Nadia K. Waheed as a panelist [3]. - Ocular will present at the Association for Research in Vision and Ophthalmology (ARVO) 2025 on May 6, 2025, discussing the HELIOS trial for diabetic retinopathy, with Neal Shah, MD, as the presenter [4]. - The company will also showcase various posters at ARVO 2025, including studies on axitinib hydrogel injections and their effects on diabetic retinopathy [5][6]. Company Presentation Highlights - Ocular Therapeutix will present on "Retina - TKI and Drug Delivery Showcase" on May 2, 2025, with Chief Strategy Officer Sanjay Nayak as the presenter [4]. - The company will also participate in the Retina World Congress (RWC) 2025, presenting updates on clinical trials related to axitinib intravitreal hydrogel and diabetic retinopathy on May 9 and 10, 2025 [7][8]. Company Overview - Ocular Therapeutix is a biopharmaceutical company focused on retinal disease therapies, with its investigational product AXPAXLI (axitinib intravitreal hydrogel) currently in Phase 3 clinical trials for wet age-related macular degeneration [9]. - The company also leverages its proprietary ELUTYX technology in its commercial product DEXTENZA, an FDA-approved treatment for ocular inflammation and pain [10].

 Kelowna, British Columbia – April 28, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock  (or pre-funded warrants in lieu thereof) at a purchase price of $1.00 per share (or per pre-funded warrant in lieu thereof)   Other than t ...

Core Insights - Galmed Pharmaceuticals has signed a binding term-sheet with Entomus for a license agreement to develop and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS) for sublingual administration of peptides like GLP-1 [1] - The global GLP-1 market is projected to exceed $120 billion by 2030, with peak sales outside the US expected to reach approximately $20 billion by 2032 [3] - The new sublingual formulation aims to enhance bioavailability, reduce side effects, and improve patient compliance compared to existing injectable and oral forms of semaglutide [6][9] Company Developments - The definitive agreement with Entomus will outline milestone payments and future royalty payments, expected to be finalized within 90 days [1] - The sublingual semaglutide formulation is anticipated to be approved through the expedited 505(b)(2) regulatory pathway [5][6] - Galmed aims to initially target markets with high rates of type 2 diabetes and obesity, such as India, Brazil, and the GCC region, where patent protections for semaglutide are less stringent [4][5] Industry Context - The first-pass effect in oral medications can reduce efficacy, while sublingual administration offers a non-invasive alternative that allows direct entry into the bloodstream [2] - The increasing prevalence of type 2 diabetes and obesity in various global markets creates a favorable environment for GLP-1 therapies [4] - Semaglutide, as a GLP-1 receptor agonist, has shown significant efficacy in managing blood glucose levels and promoting weight loss, positioning it as a transformative treatment option [7]

Core Insights - Halozyme Therapeutics, Inc. announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of VYVGART® 1000mg for treating chronic inflammatory demyelinating polyneuropathy (CIDP) [1][4] - VYVGART® is the first targeted IgG Fc-antibody fragment for CIDP and represents the first novel mechanism of action for CIDP treatment in over 30 years [2] - The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date [4] Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of injected drugs [5] - The company has licensed its ENHANZE® technology to major pharmaceutical companies including Roche, Takeda, and Pfizer, impacting over one million patients globally [5] - Halozyme also develops drug-device combination products aimed at enhancing patient comfort and adherence [6] Market Implications - The EC decision on the marketing authorization application is expected within approximately two months, which will apply to all 27 EU Member States and additional countries [1][4] - The approval of VYVGART® could provide a groundbreaking treatment option for patients with rare autoimmune diseases across Europe [3]

Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and Int ...

Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and In ...

Core Insights - Cingulate Inc. has announced the development of CTx-2103, a once-daily formulation of buspirone aimed at addressing anxiety disorders, which represent a significant market opportunity valued at $5.5 billion in the U.S. and $11.6 billion globally [1][4] - The company has received a $3 million grant to accelerate the development of CTx-2103, which will be disbursed in three tranches based on product development milestones [2] - CTx-2103 is expected to reduce reliance on benzodiazepines, which are associated with withdrawal and dependency issues, thus providing a safer alternative for patients [1][4] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform [1][8] - The company aims to improve treatment outcomes for patients with conditions requiring frequent dosing regimens, with an initial focus on ADHD and anxiety disorders [8] Product Details - CTx-2103 is a novel multi-release tablet of buspirone that utilizes Cingulate's PTR™ technology, designed to provide controlled drug release at specific times [4][6] - Buspirone, the active ingredient, is a non-benzodiazepine anxiolytic that may have a lower side-effect profile compared to traditional anxiolytics, with no associated risk of physical dependence [4][5] Market Context - Anxiety disorders are the most prevalent mental health issues in the U.S., affecting an estimated 31% of adults at some point in their lives, highlighting a significant unmet medical need [4][5] - The COVID-19 pandemic has exacerbated anxiety-related disorders, increasing the urgency for effective treatment options [5]